The treatment combination of 2-deoxyglucose (2-DG), G6P competitor, and sorafenib increased HCC cell death, inhibited colony formation, decreased cell motility and MMP9 expression, and had tumor-suppression effects [194,195]. This evidence concerns the gene MMP9 and hepatocellular carcinoma.